23andMe Holding Co - ME Enterprise Value-to-Revenue Multiple

23andMe (ME) - corporate logo

Is it worth investing in 23andMe Holding Co. (ME), a pioneer of personalized genetics that has built a massive DNA archive for drug development? The shift in EV/Sales valuation provides the answer, with indicating the current level. The business relies on valuable biodata for pharma behemoths, despite elastic demand in the retail sector. However, a profound crisis of trust and declining interest in DNA testing threaten the company's survival.

23andMe Inc - ME EV/Sales Multiple (period 07/04/2022 - 11/20/2026)

ME (23andMe Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:
Fundamental company valuation:23andMe Holding Co., ME
Core merchandise of 23andMe Holding Co

For a fundamental valuation of 23andMe Holding Co. (ME), it is critical to understand the ratio of enterprise value to annual sales on an unlevered basis. By analyzing the EV/Revenue trend, an investor determines the market revaluation of assets, where the stability of this metric confirms the effectiveness of diversification between B2C tests and B2B partnerships with pharma behemoths, minimizing data commercialization risks.

Competitor analysis for 23andMe Holding Co.

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Insight Molecular Diagnostics, Inc. (IMDX) - Company Value to Revenue|TRIB: EV/Sales Multiple|ProPhase - Business Value to Revenue|Enterprise Value-to-Revenue Ratio ainos.com|CODX: Business Value to Revenue|Enterprise Value-to-Revenue Ratio HeartSciences (HSCS)|Company Value to Revenue Biomerica Inc. BMRA|EV/Sales Multiple CDIO (Cardio Diagnostics)|ONCO - Company Value to Revenue|VRAX: Company Value to Revenue|bluejaydx.com (BJDX) - Company Value to Revenue|AWH: EV/Sales Multiple|AXDX: Enterprise Value-to-Revenue Coefficient|CNTG (CENTOGENE N.V.) - EV/Sales Multiple|Company Value to Revenue Enzo Biochem, Inc. (ENZ)|FRES - Enterprise Value to Sales Volume|Genetic Technologies Limited (GENE) - Enterprise Value-to-Sales Ratio|Psychemedics Inc - Company Value to Revenue